Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 15/20 | 0.43 |
| ▸ | IGF1R | P08069 | 2/20 | 0.40 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.40 |
| ▸ | PLK1 | P53350 | 1/20 | 0.39 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26397057 | 0.89 | EGFR (0.47) | JAK3EGFRIGF1RNTRK1 | |
| SCHEMBL26397198 | 0.88 | EGFR (0.47) | EGFRIGF1RPLK1ALK | |
| SCHEMBL26384067 | 0.78 | EGFR (0.59) | JAK3EGFRNTRK1 | |
| SCHEMBL26397329 | 0.78 | NTRK1 (0.48) | JAK3EGFRIGF1RNTRK1 | |
| SCHEMBL26395755 | 0.78 | ALK (0.57) | EGFRIGF1RPLK1ALK | |
| SCHEMBL26397089 | 0.78 | EGFR (0.47) | JAK3EGFRIGF1RPLK1ALK | |
| SCHEMBL26384092 | 0.78 | EGFR (0.53) | EGFRIGF1RPLK1ALK | |
| SCHEMBL26401884 | 0.78 | EGFR (0.48) | EGFRIGF1RPLK1ALK | |
| SCHEMBL26395787 | 0.76 | ULK1 (0.64) | EGFRIGF1RPLK1ALK | |
| SCHEMBL26384063 | 0.75 | CDK7 (0.43) | EGFRIGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230310428-A1 | EGFR INHIBITOR AND PREPARATION METHOD AND USE THEREOF | Hongyun Biotech Co., Ltd. (CN) | 2023-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230310428-A1 | EGFR INHIBITOR AND PREPARATION METHOD AND USE THEREOF | EGFR, ERBB2, ERBB4 | JAK3 115/4885EGFR 1/4885IGF1R 73/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.